You have 9 free searches left this month | for more free features.

City

Guangzhou (3)

Beijing (2)

Condition

Non-small Cell Lung Cancer (2)

Glioblastoma (1)

Glioma (1)

Non-Small Cell Lung Cancer (1)

Overall Status

Active, not recruiting (2)

Completed (2)

Recruiting (1)

Sign in for free

Phase

phase 1 (2)

phase 2 (1)

phase 2/phase 3 (1)

phase 3 (1)

Sponsor

Beijing Pearl Biotechnology Limited Liability Company (5)

Collaborator

Intervention

plb1001 (5)

cisplatin combined with etoposide (1)

temozolomide (1)

Study Documents

Intervention Type

drug (5)

Funder Type

Industry (5)

Study Type

Interventional (5)

plb1001

Showing 1 - 5 of 5

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Glioblastoma Trial in Beijing (PLB1001, Temozolomide, Cisplatin combined with Etoposide)

Active, not recruiting

Glioblastoma

PLB1001
+2 more

Beijing, Beijing, China

Beijing Tiantan Hospital,Capital Medical University

Oct 27, 2023

NSCLC Trial in Guangzhou (PLB1001)

Active, not recruiting

Non-small Cell Lung Cancer

PLB1001

Guangzhou, Guangdong, China

Guangdong Provincial People's Hospital

Aug 15, 2023

Glioma Trial in Beijing (PLB1001)

Completed

Glioma

PLB1001

Beijing, Beijing, China

Beijing Shijitan Hospital,CMU

Mar 2, 2020

NSCLC Trial in Guangzhou (PLB1001)

Recruiting

Non-small Cell Lung Cancer

PLB1001

Guangzhou, Guangdong, China

Guangdong General Hospital

Feb 5, 2020

NSCLC Trial in Guangzhou (PLB1001)

Completed

Non-Small Cell Lung Cancer

PLB1001

Guangzhou, Guangdong, China

Guangdong General Hospital

Nov 20, 2019